8-K: SELLAS Life Sciences' REGAL Trial for AML Treatment Shows Positive Interim Results

SELLAS Life Sciences' Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) successfully passed its interim analysis, with the Independent Data Monitoring Committee (IDMC) recommending continuation of the trial without modification.

Summary

• SELLAS Life Sciences announced positive results from the interim analysis of its Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML).
• The Independent Data Monitoring Committee (IDMC) recommended the trial continue without modifications after reviewing unblinded data.
• The IDMC confirmed that GPS exceeded predetermined futility criteria and noted no safety concerns.
• Fewer than 50% of enrolled patients were confirmed deceased after a median follow-up of 13.5 months, suggesting a median survival exceeding 13.5 months compared to a historical median survival of 6 months with conventional therapy.
• 80% of randomly selected REGAL GPS patients showed a specific T-cell immune response, surpassing results from a previous Phase 2 study.
• The next and final analysis is planned upon reaching 80 events (deaths).
• The company is preparing for a Biologics License Application (BLA) submission.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the successful interim analysis of the REGAL trial and the potential for GPS to become a new treatment option for AML. The IDMC's recommendation to continue the trial without modifications and the promising survival data contribute to the positive sentiment.

Positives

• The IDMC recommended the continuation of the REGAL trial without modifications, indicating confidence in the potential of GPS.
• GPS exceeded the predetermined futility criteria, suggesting it has a reasonable chance of demonstrating efficacy.
• No safety concerns were noted by the IDMC.
• The median survival of patients in the trial appears to be significantly longer than historical survival rates with conventional therapy.
• GPS demonstrated a strong T-cell immune response in a high percentage of patients.

Risks

• The final analysis of the REGAL trial is still pending and will determine the ultimate success of GPS.
• Regulatory approval is not guaranteed, even with positive clinical trial results.
• The company's forward-looking statements are subject to risks and uncertainties, including those related to oncology product development and regulatory approval.

Future Outlook

The company anticipates reaching 80 events (deaths) in the REGAL trial this year, triggering the final analysis and potentially leading to a BLA submission for GPS as a treatment for AML.

Management Comments

• Angelos Stergiou, MD, ScD hc, President and Chief Executive Officer of SELLAS, stated that the positive outcome of the interim analysis marks the most significant milestone for the GPS program to date.
• Dr. Stergiou believes that GPS could become a transformative treatment option for AML, offering hope to patients with limited choices.
• Dr. Yair Levy believes that if approved, GPS would be highly accepted by the medical community and patients, and would become a standard-of-care in this high unmet need population.

Industry Context

The announcement highlights the ongoing efforts to develop new and effective treatments for AML, a challenging hematologic malignancy with a high unmet need. The potential approval of GPS could provide a new standard of care for patients in second complete remission (CR2), a population with limited treatment options.

Comparison to Industry Standards

• The reported median survival exceeding 13.5 months in the REGAL trial is compared to a historical median survival of 6 months for conventional therapy in a similar patient population, suggesting a significant improvement.
• The 80% GPS-specific immune response observed in the REGAL trial surpasses the 64% response rate seen in the previous Phase 2 study, indicating a potentially enhanced immune response.
• The document mentions that no drug has yet been approved specifically for maintenance of remission in AML patients in CR2, further emphasizing the significance of this development.

Stakeholder Impact

• The positive interim results offer hope to AML patients and their families.
• Successful completion of the REGAL trial and potential approval of GPS could benefit SELLAS shareholders.
• The development of a new treatment option for AML could improve the standard of care for this disease.

Next Steps

• The company will continue the REGAL trial until 80 events (deaths) are reached, triggering the final analysis.
• SELLAS is preparing for a Biologics License Application (BLA) submission for GPS.

Key Dates

Keywords

SELLAS Life Sciences, Galinpepimut-S, GPS, REGAL trial, Acute Myeloid Leukemia, AML, IDMC, Clinical Trial, Biologics License Application, BLA, Oncology, Immunotherapy